These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Moss RB Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714 [TBL] [Abstract][Full Text] [Related]
44. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. Molfino NA; Kuna P; Leff JA; Oh CK; Singh D; Chernow M; Sutton B; Yarranton G BMJ Open; 2016 Jan; 6(1):e007709. PubMed ID: 26739717 [TBL] [Abstract][Full Text] [Related]
46. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. Parulekar AD; Kao CC; Diamant Z; Hanania NA Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019 [TBL] [Abstract][Full Text] [Related]
49. Targeting airway inflammation: novel therapies for the treatment of asthma. Walsh GM Curr Med Chem; 2006; 13(25):3105-11. PubMed ID: 17073650 [TBL] [Abstract][Full Text] [Related]
50. Lebrikizumab for the treatment of asthma. Antoniu SA Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950 [TBL] [Abstract][Full Text] [Related]
51. [New drugs for severe asthma]. Sattler C; Malrin R; Garcia G; Humbert M Presse Med; 2016 Nov; 45(11):1043-1055. PubMed ID: 27836376 [TBL] [Abstract][Full Text] [Related]
52. Pharmacological management of asthma. McDonald C; Lipp J Aust Fam Physician; 1998; 27(1-2):64-8, 70. PubMed ID: 9503709 [TBL] [Abstract][Full Text] [Related]
53. Recent trends and directions in the rationalization of pharmacotherapy of bronchial asthma: probing for alternatives. Das BP; Sethi A Kathmandu Univ Med J (KUMJ); 2006; 4(3):368-78. PubMed ID: 18603937 [TBL] [Abstract][Full Text] [Related]
54. Targeting T cells for asthma. Heijink IH; Van Oosterhout AJ Curr Opin Pharmacol; 2005 Jun; 5(3):227-31. PubMed ID: 15907907 [TBL] [Abstract][Full Text] [Related]
55. Immunomodulation as asthma therapy: where do we stand? Barnes PJ Eur Respir J Suppl; 1996 Aug; 22():154s-159s. PubMed ID: 8871062 [TBL] [Abstract][Full Text] [Related]
56. Drug therapy of childhood asthma. Balachandran A; Shivbalan S; Subramanyam L Indian J Pediatr; 2001 Sep; 68 Suppl 4():S12-6. PubMed ID: 11980463 [TBL] [Abstract][Full Text] [Related]
57. BuShenYiQi Formula strengthens Th1 response and suppresses Th2-Th17 responses in RSV-induced asthma exacerbated mice. Wang J; Wu J; Kong L; Nurahmat M; Chen M; Luo Q; Li B; Wu X; Dong J J Ethnopharmacol; 2014 May; 154(1):131-47. PubMed ID: 24704667 [TBL] [Abstract][Full Text] [Related]
58. Cytokine antagonists for the treatment of asthma: progress to date. Antoniu SA BioDrugs; 2009; 23(4):241-51. PubMed ID: 19697966 [TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Matera MG; Rogliani P; Calzetta L; Cazzola M Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638 [TBL] [Abstract][Full Text] [Related]
60. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. Mitchell J; Dimov V; Townley RG Curr Opin Investig Drugs; 2010 May; 11(5):527-34. PubMed ID: 20419598 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]